Twist Bioscience Corporation announced preliminary, unaudited revenue results for the first quarter of fiscal 2026, ended December 31, 2025. The company reported total revenue of approximately $103.7 million (+/- $0.2 million), representing a 17% increase compared to the same period in fiscal 2025 and exceeding the previously provided guidance of $100 to $101 million. Revenue from DNA Synthesis and Protein Solutions grew 27% to approximately $51.1 million (+/- $0.1 million) for the quarter. Revenue from NGS Applications reached approximately $52.6 million (+/- $0.1 million), ahead of guidance expectations. Excluding one large NGS Applications customer transitioning their assay from research to commercial, NGS Applications revenue increased 18% compared to the same period in the prior year. The company will release full financial results for the first quarter of fiscal 2026 on February 2, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581280-26-000012), on January 12, 2026, and is solely responsible for the information contained therein.